Stock BTTX BETR THER
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

BETR THER Stock

Equities

BTTX

US62402D1054

Chart BETR THER

Dynamic Chart

Latest news about BETR THER

Mountain Crest Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Mountain Crest Acquisition Corp. II(NasdaqCM:BTTX) added to NASDAQ Composite Index CI
Mountain Crest Acquisition Corp. II(NasdaqCM:BTTX) dropped from NASDAQ Composite Index CI
Better Therapeutics, Inc. completed the acquisition of Mountain Crest Acquisition Corp. II (“MCAD”) from Mountain Crest Capital LLC and others in a reverse merger transaction. CI
Mountain Crest Acquisition Corp. Ii Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Mountain Crest Acquisition Corp. Ii Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Mountain Crest Acquisition II : Better Therapeutics To Go Public Via Merger With SPAC MT
Better Therapeutics, Inc. agreed to acquire Mountain Crest Acquisition Corp. II (“MCAD”) from Mountain Crest Capital LLC and others in a reverse merger transaction for approximately $150 million. CI
Mountain Crest Acquisition Corp. Ii Announces Earnings Results for the Period from July 31, 2020 to December 31, 2020 CI
Mountain Crest Acquisition Corp. II(NasdaqCM:BTTX) added to NASDAQ Composite Index CI
Mountain Crest Acquisition Corp. II announced that it has received $1.85 million in funding from Mountain Crest Capital Llc, Chardan Capital Markets, LLC CI
Mountain Crest Acquisition Corp. II has completed an IPO in the amount of $50 million. CI
Mountain Crest Acquisition Corp. II has filed an IPO in the amount of $50 million. CI
Mountain Crest Acquisition Corp. II announced that it expects to receive $1.85 million in funding from Mountain Crest Capital Llc, Chardan Capital Markets, LLC CI
More news

Press releases BETR THER

MOUN CRES : Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K PU
MOUN CRES : Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results - Form 8-K PU
MOUN CRES : Better Therapeutics Appoints Frank Karbe as Chief Executive Officer - Form 8-K PU
MOUN CRES : Better Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results - Form 8-K PU
MOUN CRES : KOL Call Discussing Better Tx's Top Line Results for BT-001 283.3 KB PU
More press releases

Company Profile

Mountain Crest Acquisition Corp II is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to pursue prospective targets that are in North America. The Company has not identified any specific business combination.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. BTTX Stock